核心财务数据

　　Elevai Labs公布2026年第一季度财报。公司报告期内营收为30.5万美元，相比去年同期的86.8万美元大幅下降65%。净亏损为222.9万美元，较去年同期的净亏损142.5万美元进一步扩大，合每股亏损0.13美元。

　　业务背景与现金流

　　Elevai Labs是一家专注于医学美容领域的生物技术公司，主要开发基于外泌体的创新护肤产品。截至季末，公司现金及现金等价物为36.4万美元，较上一季度末有所减少。研发费用维持在较高水平，主要用于推进其核心产品线的临床试验和配方优化。

　　后续发展

　　公司在财报中表示，管理层正积极寻求融资渠道以支持持续运营。公司同时强调了其在高端医美市场的产品布局，预计未来将通过扩大营销投入来提升品牌知名度和市场份额。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.